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Colorectal carcinomas that are mismatch repair (MMR)-deficient in the absence of MLH1 promoter methylation or germline
mutations represent Lynch-like syndrome (LLS). Double somatic events inactivating MMR genes are involved in the etiology of
LLS tumors. Our purpose was to define the clinical and broader molecular hallmarks of LLS tumors and the population
incidence of LLS, which remain poorly characterized. We investigated 762 consecutive colorectal carcinomas operated in
Central Finland in 2000–2010. LLS cases were identified by a stepwise protocol based on MMR protein expression, MLH1
methylation and MMR gene mutation status. LLS tumors were profiled for CpG Island Methylator Phenotype (CIMP) and
somatic mutations in 578 cancer-relevant genes. Among 107 MMR-deficient tumors, 81 (76%) were attributable to MLH1
promoter methylation and 9 (8%) to germline mutations (Lynch syndrome, LS), leaving 14 LLS cases (13%) (3 remained
unclassified). LLS carcinomas were diagnosed at a mean age of 65 years (vs. 44 years in LS, p < 0.001), had a proximal to
distal ratio of 1:1, and all were BRAF V600E-negative. Two somatic events in MMR genes were identifiable in 11 tumors (79%).
As novel findings, the tumors contained an average of 31 nonsynonymous somatic mutations/Mb and 13/14 were
CIMP-positive. In conclusion, we establish the epidemiological, clinical and molecular characteristics of LLS in a population-
based study design. Significantly more frequent CIMP-positivity and lower rates of somatic mutations make a distinction to
LS. The absence of BRAF V600E mutation separates LLS colorectal carcinomas from MLH1-methylated colorectal carcinomas
with CIMP-positive phenotype.
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Lynch syndrome; LSRFi: the National LS registry of Finland; MethyQESD: methylation-quantification of endonuclease-resistant DNA; MMR:
DNA mismatch repair; MSI-H: high-degree microsatellite instability; MS-MLPA: methylation-specific multiplex ligation-dependent probe
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Introduction
Some 16% of colorectal carcinomas are hypermutated and
most of the latter show high-degree microsatellite instability
(MSI-H).1 MSI-H is a favorable prognostic factor and may
have predictive value as well, although the latter is controver-
sial and may depend on the molecular basis of MSI.2 The
most common mechanism is biallelic promoter methylation
of the DNA mismatch repair (MMR) gene MLH1 that
accounts for two-thirds of unselected cases with MSI-H.3–5
Some 12–16% of MMR-deficient colorectal cancers are attrib-
utable to an inherited germline mutation of MLH1, MSH2,
MSH6, or PMS2 combined with an inactivating somatic event
(Lynch syndrome, LS).4–6
Recent molecular advances have made it possible to distin-
guish another group of MSI-H cancers designated as Lynch-
like syndrome (LLS).7 Neither MLH1 promoter methylation
nor germline mutations (LS) explain LLS tumors; instead, two
somatic mutational events inactivating a given MMR gene are
detectable in more than half of LLS tumors.4,8–10 Apart from
MMR genes, the broader somatic mutational profiles of LLS
tumors are unknown and only limited information is available
of the clinicopathological characteristics and the incidence of
LLS in the population.4,8–10
To shed light to some of these open questions, we con-
ducted a molecular study on 762 consecutive colorectal can-
cers operated in the Jyväskylä Central Hospital district of
Finland in 2000–2010.11 The relative shares of LS, MLH1-
hypermethylated and LLS fractions of colorectal cancers were
determined. For the LLS tumors, the somatic mutation pro-
files of 578 cancer-associated genes were established and com-
pared to those of LS colorectal tumors from our previous
investigation.12 Our study provides important new informa-
tion of the molecular epidemiology and underlying develop-
mental mechanisms of LLS.
Materials and Methods
Patients and samples
We conducted a retrospective study on consecutive colorectal
carcinomas (n = 762) diagnosed in the hospital region of Cen-
tral Finland during years 2000–2010. The tumors were histo-
pathologically classified by stage and grade, after the UICC
guidelines (6th edition), as described.11 All samples used for
molecular studies were formalin-fixed paraffin embedded
(FFPE) specimens. Representative areas of normal and tumor
tissue were selected based on histological evaluation and used
for DNA isolation by a non-enzymatic protocol.13
Our study was approved by the Institutional Review Board
of the Helsinki University Central Hospital (466/E6/01) and
the ethics committee of Jyväskylä Central Hospital (Dnro
13 U/2011). The National Supervisory Authority for Welfare and
Health (Dnro 1272/04/044/07 and Dnro 10,741/06.01.03.01/2015)
approved the use of the patient registry and collection of archival
specimens.
Immunohistochemistry
Tumor representative TMA-blocks (tissue microarray) were
prepared from FFPE samples. Immunohistochemistry (IHC)
staining was performed using the LabVision Autostainer
480 (Thermo Fisher Scientific, Fremont, CA, USA) and Bright-
Visionþ polymer detection kit (ImmunoLogic BV, Duiven, The
Netherlands) to determine the expression of MMR genes
MLH1, MSH2, MSH6 and PMS2 according to a standard proto-
col.11 Samples with deficient expression of one or more of the
MMR proteins compared to positive controls were considered
MMR deficient (dMMR) whereas tumors exhibiting normal
positive staining for all four genes were MMR proficient
(pMMR).14 If the MMR status remained unclear after IHC from
TMA blocks, we performed re-analysis using sections of whole
FFPE blocks. Cases with BRAF V600E hotspot mutation were
also identified by IHC,11 which has been validated against qPCR
as a reliable method for BRAF V600E detection.15
Microsatellite instability analysis
BAT25 and BAT26 mononucleotide repeat markers, specific
and sensitive indicators of MSI-H, were used to determine the
MSI status16,17 for those samples for which MMR proficiency/-
deficiency could not be determined by IHC. Tumors unstable
for BAT25 and/or BAT26 were considered as MSI, and tumors
stable for both markers were considered microsatellite-stable
(MSS).
Exclusion of the Finnish founder mutation 1
The most prevalent LS predisposing mutation in the Finnish
population, a 3.5-kb genomic deletion of MLH1 exon 16 and
flanking introns (“Mutation 1”), is not detectable by standard
sequencing and was excluded by a mutation-specific test18 in
suspected LLS cases with absent MLH1 in tumor tissue.
What’s new?
Lynch-like syndrome (LLS), characterized by mismatch repair (MMR)-deficient colorectal tumors that lack MLH1 promoter
methylation and germline mutations, remains a diagnostic challenge. Here, LLS was found to account for about 13 percent of
MMR-deficient colorectal carcinomas in patients diagnosed in Central Finland between 2000 and 2010. While LLS tumors could
not be reliably distinguished from Lynch syndrome (LS) tumors based on clinical or histological factors, LLS tumors differed
significantly from sporadic MLH1-methylated and LS tumors DNA methylation and somatic mutation profiles. The findings
provide valuable insight into LLS and could facilitate advances in LLS diagnosis and treatment.
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Comprehensive Cancer Panel sequencing
Sixteen colorectal cancer samples in which MLH1 methylation
or LS registry information did not explain the dMMR pheno-
type, and their corresponding normal samples were included in
CCP sequencing. Sequencing was conducted in the Institute for
Molecular Medicine Finland (FIMM; Helsinki, Finland), as
described.12 Nimblegen Comprehensive Cancer Panel (Roche
Diagnostics) was used to target 578 cancer-related genes with a
4 Mb design compiled from the Sanger Institute Cancer Gene
Census Database and the NCBI Gene tests databases. The mean
target coverage was 160-fold (Supporting Information Table 1).
The variant calling pipeline (VCP 3.6) is described in Sulonen
et al.19 Alignment against the human genome GRCh37
reference-genome primary assembly was as described.12
Somatic mutation analysis of CCP data
From the panel sequencing data of paired normal and tumor
samples, VarScan 2 mutation detection algorithm version
2.3.220 was used to identify non-synonymous somatic muta-
tions (missense, nonsense, frameshift, in-frame coding deletio-
n/insertion and splice site mutations), as described.12 Variants
with VarScan somatic p-value below 0.01 were considered in
subsequent analyses. All non-synonymous sequence changes
with the possibility of being pathogenic (pathogenicity classes
3–5) are called mutations throughout this paper.
Analysis of LLS tumors for two-hit inactivation of MMR
genes
Data on MMR gene(s) pinpointed by IHC results in each LLS
tumor were retrieved from CCP sequencing and examined for
somatic mutations. Loss of heterozygosity (LOH) analysis was
based on the comparison of paired tumor and normal sam-
ples12 was performed by VarSeq (GoldenHelix®) using VCP
3.6 filtered sequencing data (.vcf-files). We followed the thresh-
olds set for strict and putative LOH in Ollikainen et al.21 Puta-
tive and strict LOH are called LOH throughout this paper.
Characterization of top-mutated genes
For each of the 578 genes targeted, we determined the propor-
tion of tumors in which a particular gene was mutant accord-
ing to our criteria for non-synonymous somatic mutations
described above. To identify top mutated genes, the cut-off
method developed earlier was applied.12 Based on the distri-
bution of mutated genes across the tumors, a cut-off of 29%
(LLS) or 28% (LS) was set, as described in detail in Supporting
Information Table 3 below.
IonTorrent sequencing
To verify CCP sequencing results for MMR genes, an Ion
Ampliseq™ (Thermo Fisher Scientific) custom panel was
designed to cover MLH1, MSH2, MSH6 and PMS2 coding
and untranslated regions. The panel was designed for
125–175 bp amplicon range and comprised 163 amplicons
covering 92.36% of the target areas. The libraries were
prepared according to the standard Ion Ampliseq™ protocol
supplied by the manufacturer. Sequencing was performed with
Ion torrent PGM (Thermo Fisher Scientific). Primary data
processing was performed on Torrent Suite™ Software
(Thermo Fisher Scientific). Variant calling was performed on
Ion reporter version 4.2 (Thermo Fisher Scientific). Variants
with less than 20× coverage were filtered.
CpG island methylator phenotype status
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) was applied to determine the CpG
island methylator phenotype (CIMP) status of LLS tumors.
We focused on promoter methylation of the CACNA1G,
IGF2, NEUROG1, RUNX3 and SOCS1 genes, for which SALSA
MS-MLPA probemix ME042-B2 (MRC Holland, Amsterdam,
The Netherlands22 was used. The cut-offs for probe-specific
hypermethylation in tumor tissue were determined against
normal mucosa DNAs as described in Valo et al.23 The hyper-
methylation threshold was defined as the mean methylation
dosage ratio (Dm) in normal mucosa plus two standard devia-
tions (if the mean Dm plus two standard deviations was lower
than 0.15, the technical threshold of 0.15 was used as a cut-
off ). The probemix contains 3–5 probes per gene, of which
methylation of ≥25% indicated methylation of the gene in
question.24 According to Weisenberger et al.,25 a sample was
considered CIMP positive when three or more out of the five
genes showed methylation. The Ogino 5/8 definition for
CIMP26 which includes three additional marker genes
(CDKN2A, MLH1 and CRABP1) was tested as an alternative.
The ME042-B2 assay also includes probes for the BRAF
V600E mutation and was used to verify the BRAF-IHC data.
MLH1 methylation analysis
MLH1 promoter methylation was studied in samples with
deficient MLH1 expression by IHC. The Methylation-
quantification of endonuclease-resistant DNA (MethyQESD)
was the primary method used. The analysis method is quanti-
tative combining methylation-sensitive digestion with real-
time PCR.27 The methylation-sensitive endonuclease Hin6I
only recognizes and cuts unmethylated CGCG sites, after
which the proportions of un-cut (methylated) and cut
(unmethylated) DNAs are determined by real-time PCR.27 As
a rule, samples with methylation percentage of 16.5% are con-
sidered methylated.27 Empirically, for the present purposes a
somewhat lower percentage (≥ 11.7%) was used since it was
supported by other data, such as parallel MLH1 methylation
analysis by MS-MLPA (MLH1 is included in the SALSA MS-
MLPA probemix ME042-B2, see above).
Statistical analyses
Statistical analyses were performed using the SPSS software,
version 24.0 (IBM SPSS Inc., Chicago, IL, USA). The applica-
bility of parametric vs. non-parametric tests was first investi-
gated. Statistical significance for the differences in mean ages
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of onset and the distributions of mutations or mutant genes
between two independent groups were analyzed by the
Mann–Whitney U test. Differences between groups of >2 were
analyzed by the Chi-square test. For pairwise comparisons of
frequency data the Fisher’s exact test was used. Two-tailed p-
values <0.05 were considered significant.
Results
Molecular stratification of colorectal carcinomas from a
population-based cohort
Among the 762 colorectal carcinomas examined, 107 showed
immunohistochemical absence of one or more MMR proteins
and were classified MMR-deficient (dMMR) (Fig. 1). MLH1
promoter methylation analysis of tumors lacking MLH1 pro-
tein identified 81 cases with MLH1 methylation (76% of all
dMMR tumors). All dMMR cases, especially those with absent
MLH1 not explained by MLH1 methylation and those with
absent MSH2, MSH6, or PMS2 protein(s), were checked
against the National LS registry of Finland (LSRFi), resulting
in the diagnosis of Lynch syndrome (LS) in eight. An addi-
tional LS case not belonging to any existing LS families (case
K14915Ca in Supporting Information Table 2) was subse-
quently found by sequencing of normal and tumor tissues of
the remaining cases (Fig. 1). Thus, LS accounted for 9 of
107 dMMR cases (8%).
Of 18 cases left when MLH1-hypermethylated cases and
LSRFi-associated LS cases were excluded, sufficient biological
material was available from 16 cases to be included in targeted
sequencing. Sequencing was unsuccessful in one; thus, a total of
three cases remained unclassified because their MLH1 methyla-
tion status or germline mutation status could not be determined.
After exclusion of case K14915Ca that revealed a germline
mutation in MLH1 (see above), fourteen cases remained with
neither hypermethylation of MLH1 nor germline mutations in
MMR genes, and were considered to represent Lynch-like syn-
drome (LLS). The LLS group constituted 13% of all dMMR cases
and 2% of the entire population-based cohort.
Mechanisms of MMR gene inactivation in LLS tumors
Immunohistochemical pattern suggested MLH1 inactivation
(absent MLH1 and PMS2) in four tumors, MSH2 inactivation
(absent MSH2 and MSH6) in six tumors, and MSH6 inactiva-
tion (selective absence of MSH6) and PMS2 inactivation (selec-
tive absence of PMS2) in two tumors each (Table 1). To address
the molecular mechanisms behind MMR gene inactivation,
panel sequencing data of normal and tumor tissues were ana-
lyzed for somatic mutations and loss of heterozygosity (LOH) of
the relevant genes. Two somatic events in MMR genes likely to
underlie MMR deficiency were identified in 11 of 14 tumors
(79%) (Tables 1 and 2). Somatic mutation accompanied by
LOH occurred in 10 tumors and two somatic mutations in one
tumor (91% and 9%, respectively, of the 11 two-hit-associated
tumors). Two tumors bore two somatic mutations and LOH,
simultaneously. Comprehensive Cancer Panel (CCP) and
IonTorrent sequencing results were highly concordant: somatic
mutations discovered by one method could be confirmed by the
other method with the exception of three tumors, in which one
of the hits was detected by CCP alone.
Mutation profiles of 578 cancer-relevant genes in LLS
tumors
CCP sequencing revealed an average of 124 nonsynonymous
somatic mutations per LLS tumor (31/Mb on average, range
2–154 mutations/Mb). Eleven of fourteen LLS tumors (79%)
could be classified as hypermutated with the commonly used
threshold of over 10 mutations per Mb (Table 1).28 An aver-
age of 82 of 578 genes were mutant per tumor; the mean was
25, if only high-frequency mutations (allele-frequency 25% or
higher) were considered. The present set of 9 LS tumors were
not available for comparison, since (with one exception) these
tumors did not enter the panel sequencing step (Fig. 1). We
previously profiled 18 LS tumors from the national LS registry
on the same sequencing platform as the present LLS tumors.12
These tumors were now re-analyzed by the same bioinformat-
ics pipeline as our LLS tumors and used for comparison. The
average number of nonsynonymous somatic mutations was
617 per LS tumor, whereas the mean number of mutant genes
was 255 (and 55 if only high-frequency mutations were con-
sidered). The corresponding figures in LLS tumors were all
significantly lower (124, p < 0.0001, 82, p < 0.0001; and
25, p = 0.010, respectively) (Table 1). The mean number of
nonsynonymous mutations in LS tumors (617) is equivalent
to 154 mutations/Mb, and all 18 LS tumors fulfilled the defini-
tion of “hypermutated” (range 38–374 mutations/Mb).
We next plotted each of the 578 genes against the number
of tumors in which it was mutant (only mutations with allele
frequencies of 25% or higher were considered). The distribu-
tion ranged from one gene (MAML2) mutant in six samples
(43%) to 354 genes without a single mutation in any of the
14 LLS samples (Supporting Information Table 3). Setting the
cut-off at 4 of 14 tumors (29%) mutant for a given gene
(in analogy to Ref. 12), 13 top mutant genes were detected in
LLS tumors (Fig. 2a). The same procedure identified 39 top
mutated genes in the 18 LS colorectal carcinomas used for
comparison (Fig. 2b). LLS and LS tumors shared four top
mutant genes (PRKDC, TCF7L2, ARID1A and RPL22).
TCF7L229 and RPL2230 contain mononucleotide repeats as
part of their transcripts and are therefore susceptible to trun-
cating mutations in MSI tumors (Supporting Information
Fig. S1 and Supporting Information Table S4). Eleven of
13 LLS-associated genes were mutant with higher frequencies
in LLS vs. LS tumors (Fig. 2a), and the difference reached sta-
tistical significance for BCOR (4/14 vs. 0/18, p = 0.028).
MAML2, which encodes a member of the Mastermind-like
family of proteins and positively regulates Notch signaling,31
showed the highest involvement in LLS tumors (6/14, 43%);
this clearly exceeded the corresponding frequency in LS
tumors 2/18 (11%). Four of six mutant tumors shared a
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recurrent 9-bp deletion that affects a polyglutamine repeat of
MAML2 and is present in the COSMIC database (Supporting
Information Table 4). Reflecting the relatively small total
numbers of cases in the LLS and LS groups, the p values for
differences were modest overall (Figs. 2a and b). Although not
reaching statistical significance, our study recapitulated the
Figure 1. A step-wise protocol to stratify 762 consecutive colorectal carcinomas first into pMMR and dMMR groups and the latter further into
MLH1-methylation positive, LS, and LLS subgroups. Four tumors did not comply with any of the four main IHC patterns and are referred to as
“Other.” Since absent MLH1 was part of the abnormal IHC phenotype in all four cases, the tumors were primarily tested for MLH1 methylation
and in the absence of demonstrable MLH1 methylation, submitted to downstream steps. Asterisk (*) indicates those three dMMR cases to
which a specific molecular subgroup could not be assigned because their MLH1 methylation status or panel sequencing status (to exclude
LS) could not be determined. [Color figure can be viewed at wileyonlinelibrary.com]
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observation by Cohen et al.32 of more frequent PIK3CA muta-
tions in LLS (4/14, 29%) than LS tumors (1/18, 7%). Detailed
mutation information for all 13 LLS-associated genes is avail-
able in Supporting Information Fig. S1 and Supporting Infor-
mation Table S4.
CpG Island Methylator phenotype status of LLS tumors
Previous studies have linked CIMP-positivity to MLH1 meth-
ylated sporadic tumors and a proportion of LS tumors,33,34
whereas no information is available for LLS tumors. There-
fore, it was of particular interest to determine the CIMP sta-
tus of the present LLS tumors. By the Weisenberger
criteria,25 all but one tumor (13/14, 93%) were CIMP-
positive (Table 1, Supporting Information Table 5). This fre-
quency was significantly higher compared to that for LS
colorectal tumors previously evaluated by the same criteria
(9/18, 50%)12 (p = 0.019). In LLS tumors, CIMP did not
affect MLH1 promoter, and IHC-analysis showed that all
LLS tumors were negative regarding BRAF V600E mutation
(see Table 3 below).
Clinicopathological characteristics of colorectal carcinoma
subgroups
The basic clinicopathological characteristics of the different
categories of colorectal carcinomas identified by molecular
stratification (Fig. 1) are shown in Table 3. LLS colorectal car-
cinomas were diagnosed at the age of 65 years on the average
vs. 44 years in the LS cases (p < 0.001), and 76 years in the
MLH1-methylated group (p < 0.001) (Table 3). LLS tumors
had a proximal to distal ratio of 1:1, whereas LS tumors
occurred primarily (89%) in the proximal part of the colon
(p = 0.086). Well-differentiated (grade 1) tumors accounted for
the majority (43%) in the LLS group, whereas poorly differenti-
ated (grade 3) tumors predominated with 59% frequency in
the LS group (p = 0.009). LLS tumors revealed the highest fre-
quency of mucinous tumors (21%) among the different tumor
categories. Information of synchronous/metachronous tumors
Figure 2. (a) Top 13 mutated genes in LLS-colorectal carcinomas. Genes affected with high-frequency mutations (mutant allele
frequency ≥ 25%) in at least 29% (4/14) of LLS tumors are shown. Mutation percentages of the same genes in LS-colorectal carcinomas are
depicted for comparison. The difference between LLS and LS was statistically significant for BCOR and non-significant for the remaining genes
by Fisher’s exact test. (b) Top 39 mutated genes in LS colorectal carcinomas. Genes affected with high-frequency mutations (mutant allele
frequency ≥ 25%) in at least 28% (5/18) of LS tumors (from Ref. 12) are shown. Mutation percentages of the same genes in LLS-colorectal
carcinomas are displayed for comparison. Exact p-values for statistically significant differences are given above the frequency bars.
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was available from 13 LLS cases. With respect to cancers of any
organs, one LLS patient was diagnosed with transitiocellular
carcinoma of the bladder and another one with tonsillar diffuse
large-cell B-cell lymphoma; the difference relative to LS
patients was borderline significant (15% vs. 56%, p = 0.074).
Discussion
Our population-based investigation of 762 colorectal carcino-
mas operated in the hospital region of Central Finland during
2000–2010 identified 107 MMR-deficient cases (14% out of
762). Tumors with MLH1 promoter methylation was the larg-
est subgroup among MMR-deficient colorectal cancers (69%),
followed by LLS (13%) and LS (8%) (Fig. 1). LLS cases were
diagnosed at a mean age of 65 years, which differed signifi-
cantly from both LS (44 years) and MLH1-methylated cases
(76 years) (Table 3). Published reports have found lower mean
or median ages at onset for LLS colorectal cancers compared
to MLH1-hypermethylated colorectal cancers, and roughly
comparable ages at onset for LLS vs. LS.5,35 Our LLS colorectal
carcinomas were equally often proximal and distal; some stud-
ies have found predilection to proximal colon in LLS.35 Grade
1 tumors predominated in the LLS group, as opposed to grade
3 in LS (Table 3), in agreement with Rodriguez-Soler et al.5
Synchronous or metachronous cancers are less common in
LLS than LS patients (Table 3 and Ref. 35), emphasizing a
sporadic non-syndromic nature of LLS.
To our knowledge, our study is the first to show a frequent
methylator phenotype (not affecting MLH1) as a feature of
LLS colorectal carcinomas. All LLS tumors except one (93%)
exhibited CIMP positivity (Table 1), compared to 50% of LS
tumors12 (p = 0.019). At present, no universal consensus exists
regarding the laboratory method, marker panel, or marker
threshold values for CIMP definition.24 We studied our sam-
ples with an alternative panel (Ogino 5/8, see Materials and
Methods) as well. The same relative trend as with the original
Weisenberger 3/5 panel was evident, but with somewhat lower
frequencies for CIMP (11/14, 79% for LLS and 7/18, 39% for
Table 3. Summary of clinicopathological data of all samples1
Lynch-like
cases
Lynch
cases
p-value
(vs. LLS)
MLH1 methylated
cases
p-value
(vs. LLS)
pMMR
cases
p-value
(vs. LLS)
Average age of onset (years) 65 44 < 0.0012 76 < 0.0012 70 0.1232
Tumor location3
Proximal 7/14 (50%) 8/9 (89%) 0.0864 60/80 (74%) 0.1054 229/653 (35%) 0.2674
Distal 7/14 (50%) 1/9 (11%) 20/80 (25%) 424/653 (65%)
Tumor grade5
1 6/14 (43%) 1/9 (11%) 0.0096 17/81 (21%) 0.1816 221/654 (43%) 0.0236
2 5/14 (36%) 3/9 (33%) 34/81 (42%) 363/654 (55%)
3 0/14 (0%) 5/9 (56%) 18/81 (22%) 42/654 (6%)
4 0/14 (0%) 0/9 (0%) 1/81 (1%) 1/654 (0.15%)
mucinous 3/14 (21%) 0/9 (0%) 11/81 (14%) 27/654 (4%)
Tumor stage5
1 2/14 (14%) 2/9 (22%) 0.7026 12/81 (15%) 0.7456 131/645 (20%) 0.7176
2a 7/14 (50%) 3/9 (33%) 31(81 (38%) 194/645 (30%)
2b 1/14 (7%) 2/9 (22%) 9/81 (11%) 24/645 (4%)
3a 0/14 (0%) 0/9 (0%) 2/81 (2%) 23/645 (4%)
3b 2/14 (14%) 2/9 (22%) 14/81 (17%) 116/645 (18%)
3c 1/14 (7%) 0/9 (0%) 12/81 (15%) 60/645 (9%)
4 1/14 (7%) 0/9 (0%) 1/81 (1%) 97/645 (15%)
BRAF V600E status
Negative 12/12 (86%) 9/9 (100%) 14 18/81 (22%) < 0.00014 604/638 (95%) 14
Positive 0 0 75/81 (70%) 34/638 (5%)
Presence of synchronous/
metachronous tumor(s)
Colorectal adenoma 6/13 (46%) 5/9 (56%) 14 24/81 (30%) 0.3364 221/634 (35%) 0.3944
Colorectal carcinoma 0/13 (0%) 2/9 (22%) 0.1564 5/81 (6%) 14 32/634 (5%) 14
Cancer of any organ 2/13 (15%) 5/9 (56%) 0.0744 NA NA
NA, Data not available.
1Three of 762 samples could not be categorized into any of the four subgroups (LLS, LS, MLH1 methylated, and pMMR).
2Calculated by Mann–Whitney U-test.
3Caecum, ascending colon and transverse colon were counted as proximal and descending colon, sigmoid colon and rectum as distal.
4Calculated by Fisher’s exact test.
5According to the UICC guidelines (6th edition).
6Calculated by Chi-square test.
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LS, p = 0.036). Both LLS and LS colorectal carcinomas show
wild-type BRAF V600E as a marked distinction to sporadic
MLH1-methylated colorectal carcinomas (Table 3; Ref. 36). In
sporadic colorectal carcinomas, MLH1 methylation, CIMP-
positivity and BRAF V600E mutation are tightly connected.25
LLS colorectal carcinomas thus exhibit a unique tumor pheno-
type that distinguishes this group from LS (CIMP-status) and
sporadic MLH1-methylated tumors (BRAF V600E status).
All LLS colorectal carcinomas except K11334Ca and
K2426Ca showed MSI (Table 1). Stable microsatellites in the
presence of abnormal MMR protein expression in the two
cases might reflect the higher sensitivity of IHC to detect
small subpopulations of tumor cells compared to MSI analy-
sis.37 All LS colorectal carcinomas had MSI-high phenotype
as shown previously.12 Despite proven MSI, targeted sequenc-
ing of 578 cancer-relevant genes revealed a significantly lower
propensity for LLS tumors to acquire somatic nonsynon-
ymous mutations compared to LS tumors (see Results). No
obvious technical reason to explain the difference exists. As
the RPL22 and TCF7L2 examples suggest (see Results), our
somatic mutation analysis is expected to correctly identify a
majority of small insertions and deletions, too, in addition to
single nucleotide variants effectively identified by the avail-
able pipelines. Moreover, the average tumor percentages were
even higher for LLS than LS tumors (59% vs. 49%, respec-
tively). The distinct epigenetic patterns (see above) and muta-
tional profiles of cancer-relevant genes (Figs. 2a and 2b)
support intrinsic biological differences between the two
tumor groups.
The unique molecular profile of CIMP without BRAF-
V600E mutation raises the question about the pathway of colo-
rectal tumorigenesis in LLS. Most colorectal carcinomas,
including those occurring in LS, are thought to develop via ade-
nomatous polyps, whereas MLH1 hypermethylated carcinomas
often arise from serrated polyps.38,39 According to histopatho-
logical review, precursor lesions were not identified in any of
our 14 LLS carcinomas. However, 6 cases showed serrated ade-
nocarcinoma features (epithelial serration, clear or eosinophilic
cytoplasm, abundant cytoplasm, vesicular nuclei, absence of or
less than 10% necrosis of total area, mucin production and cell
balls or papillary fronds in mucinous areas of the tumor).40 Six
carcinomas did not have serrated histology. Two carcinomas
had some serrated features but were not considered to repre-
sent serrated adenocarcinoma. In the series of Mas-Moya
et al.,35 colorectal cancer precursor lesion was observed in 7 out
of 16 cases and all lesions were adenomatous polyps. Molecu-
larly, APC and KRAS mutations are an integral part of
adenoma-carcinoma sequence irrespective of MSI and also
common in serrated adenomas associated with MLH1 pro-
moter methylation, although KRAS mutations are less frequent
than BRAF mutations in the latter group. Determined from our
panel sequencing data, 6 of 14 LLS tumors (43%) had truncat-
ing APC mutations. Three LLS tumors (21%) showed (non-
truncating) mutations in KRAS, with the known pathogenic
hotspots41,42 involved in two cases, G12D in one tumor and
A146T in another one. Among 18 LS colorectal carcinomas
studied for comparison, 11 (61%) and 4 (22%) were mutant for
APC and KRAS, respectively (all KRAS mutations affected the
hotspot sites, G12 V and G13D in one tumor each and A146T
in two tumors). Thus, colorectal tumorigenesis in LLS is associ-
ated with frequent APC and KRAS mutations, comparable to
LS. It has been hypothesized that mutant KRAS, like mutant
BRAF, may contribute to CIMP as they belong to the same sig-
naling pathway.34 This mechanism may explain CIMP in
BRAF-V600E negative tumors (LS and LLS). Taken together,
while the question about histology of LLS precursor lesions
requires additional investigations, our results define a molecular
pathway where APC and KRAS mutations combined with gen-
eral hypermutability (MSI) and tumor suppressor gene inacti-
vation by promoter methylation (CIMP) are important players.
Several potential clinical implications can be foreseen. The
frequent occurrence of CIMP in LLS tumors may have prog-
nostic relevance since CIMP has been shown to be associated
with worse prognosis of colorectal cancer irrespective of MSI
status.43 The predictive value of CIMP remains unsettled.43
PIK3CA mutations may predict resistance to anti-EGFR ther-
apy.44 Kloth et al.36 combined LLS and LS colorectal cancers
to a single BRAF-wild type MSI-H group and found that 15%
of the tumors showed activating mutations in ERBB2 that
might indicate responsiveness of pan-HER inhibitors. High-
frequency mutations in ERBB2 were present in 7% (1/14) of
our LLS tumors. Among the different members of the ErbB
gene family, ERBB3 revealed the most common involvement,
being one of the top mutant genes in LLS tumors (29%, 4/14;
(Fig. 2a). ERBB3 mutations occur in up to one-fifth of various
cancers overall and sensitivity to inhibitors of HER family has
been documented.45 Finally, hypermutability and neoantigen-
induced immunoreactions make MSI-H tumors good candi-
dates for PD-1 blockade-based immunotherapy.46 While no
data are available of LLS tumors specifically, Le et al.47
reported that non-Lynch patients with MMR-deficient tumors
responded significantly better than LS patients. The mecha-
nisms behind the difference remain unknown. Our observa-
tion of fewer somatic mutations in LLS vs. LS colorectal
carcinomas is by no means in conflict with the above; LLS
(like LS) tumors are MMR-deficient and hypermutable, and
the presence of certain particularly immunogenic neoantigens,
rather than the total mutational burden, may ultimately deter-
mine the response to PD-1 blockade.48
In conclusion, LLS comprises a significant share of MMR-
deficient colorectal carcinomas, ranging from 13% (our study)
to 32%.5 The reported clinicopathological features of LLS rela-
tive to the other two main groups of MMR-deficient colorectal
carcinomas vary, in part likely to reflect the rather limited
sizes of study series and/or possible geographical variation.
LLS cannot be reliably distinguished from LS on clinical (Refs.
5,35 and our study) or histological (Refs. 5,35,49 and our
study) grounds. The novel epigenetic and genetic features we
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describe for LLS colorectal carcinomas can aid in the recogni-
tion of LLS as a separate entity. Our findings shed light to the
pathogenesis of LLS carcinomas beyond MMR defects and
may facilitate targeted approaches for treatment.
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